Elsevier

Life Sciences

Volume 58, Issue 16, 15 March 1996, Pages 1301-1306
Life Sciences

Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis

https://doi.org/10.1016/0024-3205(96)00095-1Get rights and content

Abstract

To extend our evaluation of insulin-like growth factor-I (IGF-I) treatment for human demyelinating diseases, we compared effects of s.c. and i.v. IGF-I in an in vivo model with lesions resembling those seen in multiple sclerosis. Experimental autoimmune encephalomyelitis (EAE) was induced in Lewis rats with an emulsion containing guinea pig spinal cord and treatment with placebo or with s.c. or i.v. IGF-I was started when definite clinical weakness was present. IGF-I given subcutaneously significantly reduced clinical deficits and lesion severity. The clinical improvement, as measured by clinical deficit scores, stride lengths and exercise wheel rotations, was evident in 48 hrs and was comparable to that produced by the same IGF-I dose administered intravenously. Subcutaneously administered IGF-I also increased relative mRNA levels of myelin basic protein (MBP), proteolipid protein (PLP) and 2′,3′ cyclic nucleotide 3′-phosphodiesterase (CNP), thereby promoting myelin regeneration. We conclude that s.c. IGF-I produces dramatic improvement in acute, demyelinating EAE. Our results also suggest that this growth factor may be useful in treating multiple sclerosis patients with active demyelination.

References (19)

  • B.A. Barres et al.

    Cell

    (1992)
  • M.J. Carson et al.

    Neuron

    (1993)
  • K.D. Beck et al.

    Neuron

    (1995)
  • X. Liu et al.

    Mol. Cell. Neurosci.

    (1994)
  • F.A Mcmorris et al.
  • F.A. McMorris et al.

    J. Neurosci. Res.

    (1988)
  • B.A. Barres et al.

    Development

    (1993)
  • S. Komoly et al.
  • D.-L. Yao et al.

    J. Neurosci. Res.

    (1995)
There are more references available in the full text version of this article.

Cited by (61)

  • Intrathecal insulin-like growth factor 1 but not insulin enhances myelin repair in young and aged rats

    2017, Neuroscience Letters
    Citation Excerpt :

    A recent study has re-invigorated interest in insulin-like growth factor 1 (IGF-1) as a potential therapy for neuro-inflammation [1]. Whereas IGF-1 was shown to be a potent promotor of developmental myelin formation [33], its potential to enhance remyelination remained controversial [6,27,32]. The functionally and structurally related hormone insulin could yet be another approach to boost remyelination.

  • Kinematic gait parameters are highly sensitive measures of motor deficits and spinal cord injury in mice subjected to experimental autoimmune encephalomyelitis

    2017, Behavioural Brain Research
    Citation Excerpt :

    Second, these decreases were associated with reduced average hip and knee angles over the entire step cycle, suggestive of an inability to extend these joints. These deficits may contribute to the decrease in stride length and walking speed observed for both EAE rodents and MS patients [36,76–78] Two of the most common gait deficits in these neurodegenerative conditions are: 1) decreased ability to lift the foot from the ground causing foot drop and 2) reduced walking speed corresponding to a pronounced weakness in the distal muscles of the leg (ankle dorsal and plantar flexors) [63,70,71]. Consistent with these findings, we have shown that toe height is progressively reduced with increased EAE severity while walking speed is known to be decreased by EAE [9].

  • The role of growth factors as a therapeutic approach to demyelinating disease

    2016, Experimental Neurology
    Citation Excerpt :

    For example, in agreement with the cuprizone results, in acute rat EAE IGF-I, injected peripherally during the onset of disease, reduces maximum clinical scores as well as lesion severity, and promotes a faster recovery (Liu et al., 1995, 1997). It also reduces the size and number of demyelinating lesions and upregulates myelin related protein mRNAs (Yao et al., 1995, 1996). In a chronic relapsing mouse EAE model, IGF-I treatment also reduces clinical deficits (Li et al., 1998).

  • Insulin-like growth factor-I mitigates motor coordination deficits associated with neonatal alcohol exposure in rats

    2009, Neurotoxicology and Teratology
    Citation Excerpt :

    Thus, interference with IGF-I signaling may contribute to alcohol-related neuroteratogenicity. The possibility that IGF-I could serve as a potential treatment for fetal alcohol effects is strengthened by evidence that IGF-I can protect against other CNS insults [22,107,110], enhancing both neuronal generation and growth as well as white matter production. In fact, IGF-I has been shown to attenuate the neuropathological effects of developmental alcohol exposure.

View all citing articles on Scopus
View full text